GRI Bio, Inc. (GRI) shares jumped 37.17 percent to $2.14 on Thursday, rising $0.58, after the biotechnology company reported encouraging interim results from its ongoing Phase 2a trial of GRI-0621 for Idiopathic Pulmonary Fibrosis. GRI Bio stock traded between $1.96 and $2.87 after opening at $2.12, compared with a prior close of $1.56 on the Nasdaq. Volume spiked to 57.6 million shares, far above the average of 170,000.
The stock's 52-week range is $1.10 to $30.43.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.